Effect of menatetrenone, a vitamin K2 analog, on recurrence of hepatocellular carcinoma after surgical resection: A prospective randomized controlled trial

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5415-5420

  Ishizuka, Mitsuru ^a   Kubota, Keiichi ^a   Shimoda, Mitsugi ^a   Kita, Junji ^a   Kato, Masato ^a   Park, Kyung Hwa ^a   Shiraki, Takayuki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Des carboxy prothrombin; Disease free survival; Hepatocellular carcinoma recurrence; Menatetrenone; Vitamin K2 analog

Indexed keywords

MENATETRENONE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME;

AGED; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; VITAMIN K 2;

EID: 84872535416     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y and Ikai I: Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 49: 589-594, 2008.
2. Lord R, Suddle A and Ross PJ: Emerging strategies in the treatment of advanced hepatocellular carcinoma: The role of targeted therapies. Int J Clin Pract 65: 182-188, 2011.
3. Furie B, Bouchard BA and Furie BC: Vitamin K-dependent biosynthesis of carboxyglutamic acid. Blood 93: 1798-1808, 1999.
4. 2analog, on disease recurrence and survival in patients with hepatocellular carcinoma. Cancer 106: 867-872, 2006.
5. Kakizaki S, Sohara N, Sato K, Suzuki H, Yanagisawa M, Nakajima H, Takagi H, Naganuma A, Otsuka T, Takahashi H, Hamada T and Mori M: Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. Hepatology 22: 518-522, 2007.
6. Yoshida H, Shiratori Y, Shiina S, Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, Kawabe T, Kawazoe S, Kobashi H, Kasugai H, Osaki Y, Araki Y, Izumi N, Oka H, Tsuji K, Toyota J, Seki T, Osawa T, Masaki N, Ichinose M, Seike M, Ishikawa A, Ueno Y, Tagawa K, Kuromatsu R, Sakisaka S, Ikeda H, Kuroda H, Kokuryu H, Yamashita T, Sakaida I, Katamoto T, Kikuchi K, Nomoto M and Omata M: Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 54: 532-540, 2011.
7. Nanashima A, Sumida Y, Abo T, Shindou H, Fukuoka H, Takeshita H, Hidaka S, Tanaka K, Sawai T, Yasutake T, Nagayasu T, Omagari K and Mine M: Modified Japan Integrated Staging is currently the best available system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol 41: 250-256, 2006.
8. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Yoshida H, Shiina S and Omata M: Des-γcarboxyl prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer 91: 561-569, 2001.
9. Sawada T, Kubota K, Kita J, Kato M, Shiraki T, Park K and Shimoda M: Clinical outcome of hepatectomy for hepatocellular carcinoma ≤2 cm. World J Surg 35: 377-385, 2011.
10. Yoshiji H, Noguchi R, Toyohara M, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M and Fukui H: Combination of vitamin K and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 51: 315-321, 2009.
11. Wei G, Wang M, Hyslop T, Wang Z and Carr BI: Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo . Int J Cancer 127: 2949-2958, 2010.
12. 2analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor κB actibation. Clin Cancer Res 13: 2236-2245, 2007.
13. 2analogue. Oncol Rep 22: 599-604, 2009.